{
    "patient": {
        "Name": "Timothy Strickland",
        "DateOfBirth": "1979-01-19",
        "Sex": "Female",
        "Diagnosis": "Medullary thyroid cancer",
        "BodyPart": "Thyroid",
        "Physician": "Dr. William Hays",
        "TreatingInstitution": "Welch and Sons"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Thyroid",
            "CollectedDate": "2024-02-04",
            "ReceivedDate": "2024-02-06",
            "TumorPercentage": "77%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-02-05",
            "ReceivedDate": "2024-02-07"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "PTCH1",
                "DNA Alteration": "c.3583A>T",
                "GeneMutation": "p.T1195S Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "18.3%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Frameshift-GOF",
                "VariantAlleleFraction": "14.45%"
            },
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.S346P Frameshift-GOF",
                "VariantAlleleFraction": "12.29%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "KIT",
            "NCSTN"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "16 m/Mb",
            "Tmbpercentile": "15%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "MYCN",
                "DNA Alteration": "c.131C>T",
                "GeneMutation": "p.P44L Frameshift-GOF",
                "VariantAlleleFraction": "25.0%"
            },
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5437G>A",
                "GeneMutation": "p.D1810H Stopgain-LOF",
                "VariantAlleleFraction": "2.01%"
            },
            {
                "Gene": "TLR8",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N515H Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "4.13%"
            },
            {
                "Gene": "MTOR",
                "DNA Alteration": "c.5664C>A",
                "GeneMutation": "p.G1954R Frameshift-LOF",
                "VariantAlleleFraction": "9.31%"
            },
            {
                "Gene": "ZEB2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.H1038R Frameshift-GOF",
                "VariantAlleleFraction": "1.33%"
            },
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Nonsense-GOF",
                "VariantAlleleFraction": "2.46%"
            }
        ],
        "Germline": [
            {
                "Gene": "MYCN",
                "DNA Alteration": "c.131_132delinsTT",
                "GeneMutation": "p.P44L Spliceregionvariant-LOF",
                "Condition": "myself"
            },
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.101G>T",
                "GeneMutation": "p.G34R Frameshift-LOF",
                "Condition": "choice"
            }
        ]
    },
    "low coverage regions": [
        "TOP2A",
        "HBB",
        "NCSTN"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "PTCH1",
                "DNA Alteration": "c.3583A>T",
                "GeneMutation": "p.T1195S Missensevariant(exon2)-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "18.3%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Frameshift-GOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "14.45%"
            },
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.S346P Frameshift-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "12.29%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-02-03"
    },
    "other": {
        "ReportId": "7562",
        "ReportDate": "2024-02-04",
        "SignedBy": "William Hays",
        "Supervisor": "Dr. Dr. Joy Shelton MD"
    }
}